arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.


Managing the Acutely Ill Asthma Patient and the Post Emergency Department Intervention


GOAL
The goal of this issue is to provide emergency medicine physicians with the latest information on the most current trends in treatment and management of the acutely ill asthma patient.

TARGET AUDIENCE
This activity is designed for emergency medicine physicians. There are no prerequisites.

LEARNING OBJECTIVES
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, participants should be able to:

  • Identify the pathophysiology of asthma.
  • Demonstrate knowledge of the diagnosis and assessment of the asthma patient in the emergency department (ED).
  • Understand the need for appropriate diagnostic and therapeutic interventions for the ED asthma patient in the acute state.
  • Identify the appropriate post-care treatment options for the ED asthma patient.
  • Recommend post-care prevention strategies and techniques for asthma patients.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

The estimated time to complete this educational activity: 1.5 hours.

Release date: June 30, 2003. Expiration date: June 30, 2005.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

This program is supported by an unrestricted educational grant from GlaxoSmithKline.

Full Disclosure Policy Affecting CME Activities:
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Program Director and Participating Faculty reported the following:

PROGRAM CHAIR

    Arjun Chanmugam, MD, FACEP
    Assistant Professor of Emergency Medicine
    Department of Emergency medicine
    Johns Hopkins University School of Medicine
    Baltimore, Maryland
    • Dr Chanmugam reports he has no financial or commercial relationships to disclose.

PARTICIPATING FACULTY

    Carlos A. Camargo, Jr. MD, Dr.P.H.
    Assistant Professor of Medicine,
    Department of Emergency medicine
    Harvard Medical School
    Assistant Professor of Epidemiology
    Harvard School of Public Health
    Director, EMNet Coordinating Center
    Boston, Massachusetts
    • Dr Camargo reports receiving grant/research support from Abbott, AstraZeneca, Aventis, Boehringer Ingelheim, Bristol-Myers Squibb, ClinTrials Research, Cubist Pharmaceuticals, Dey Laboratories, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Merck Research Laboratories, Monaghan Medical Corporation, Roche Laboratories, Scherin/Key Corportation, Sepracor; and serving as a consultant to Abbott, AstraZenaca, Aventis, Boehringer Ingelheim, ClinTrials Research, Dey Laboraories, Discovery Laboratories, GlaxoSmithKline, LEK Consluting, Merck Research Laboratories, Novation, Sepracor.

    James F. Donohue, MD
    Professor of Medicine
    Department of Medicine
    Chief of Pulmonary Division
    Division of Pulmonary Diseases and Critical Care Medicine
    The University of North Carolina School of Medicine
    Chapel Hill, North Carolina
    • Dr Donohue reports receiving grant/research support from GlaxoSmithKline, Boehringer Ingelheim, and Aventis; serving as a consultant to GlaxoSmithKline and Boehringer Ingelheim.

Notice:
In accordance with the ACCME Standards for Commercial Support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

The following faculty member(s) have disclosed that their presentations have referenced the following unlabeled/unapproved uses of drugs or products:

Dr Carlos Camargo: Intravenous Magnesium Sulfate (MgSO4), Heliox, IV Montelukast, Inhaled Corticosteroids

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

Over the past 20 years, asthma has emerged as a major public health problem in the United States. Nearly 15 million Americans have asthma, including almost 5 million children. Asthma accounts for 2 million visits to the emergency department (ED) per year. It is the leading cause of ED use among children and young adults in the United States. The costs of asthma have increased to $12.7 billion in 1998. However, despite in-hospital quality care, 30% of asthma patients have a relapse within a few weeks to months of discharge, leading to recurrent use of EDs for emergency rescue care. In addition, asthma morbidity and mortality rises sharply once a relapse occurs.





Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.